Abstract | OBJECTIVE: To review the pharmacology, pharmacokinetics, clinical efficacy, and safety of eplerenone, a new selective aldosterone blocker. DATA SOURCES: Primary literature and review articles were obtained via MEDLINE search (1966-April 2002). Additional studies and abstracts were identified from the bibliographies of reviewed literature. STUDY SELECTION AND DATA EXTRACTION: DATA SYNTHESIS: CONCLUSIONS:
Eplerenone appears to be a promising drug in a new class of agents called selective aldosterone blockers. The drug may be approved for treatment of hypertension in 2002. Additional studies are ongoing that may provide information on other clinical uses for this medication.
|
Authors | Alan J Zillich, Barry L Carter |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 36
Issue 10
Pg. 1567-76
(Oct 2002)
ISSN: 1060-0280 [Print] United States |
PMID | 12243608
(Publication Type: Journal Article, Review)
|
Chemical References |
- Mineralocorticoid Receptor Antagonists
- Spironolactone
- Eplerenone
|
Topics |
- Animals
- Clinical Trials as Topic
- Eplerenone
- Heart Failure
(drug therapy)
- Humans
- Hypertension
(drug therapy)
- Mineralocorticoid Receptor Antagonists
(adverse effects, pharmacokinetics, pharmacology, therapeutic use)
- Spironolactone
(adverse effects, analogs & derivatives, pharmacokinetics, pharmacology, therapeutic use)
|